BioXcel Therapeutics Inc. (BTAI)
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
Mereo BioPharma Reports Second Quarter 2025 Financial Results
Intensity Therapeutics, Inc. Regains Compliance with Nasdaqs Minimum Stockholders Equity Requirement
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
"Prime Time," a Branded Peyronies Disease Commercial forXIAFLEX® (collagenase clostridium histolyticum)
New Form 8-K - VERU INC. Filed: 2025-08-12 AccNo: 0001437749-25-026037 Size: 222 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
ADC - ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update